Clinical trials · New York, NY
Crohn’s disease clinical trials in New York
We’re tracking 46 recruiting crohn’s disease studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
New York, New YorkAges 18 years+ - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
New York, New YorkAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
New York, New YorkAges 18 years+ - NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
New York, New YorkAges 18–75 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
New York, New YorkAges 18–75 - NCT06512597Recruiting
Behavioral therapy for active Crohn's disease
This study tests whether a behavioral therapy program can help people with active Crohn's disease feel better when they start a new biologic medication. You'll get extra support to manage stress and symptoms while you and your doctor adjust your treatment.
New York, New YorkAges 18–65 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
New York, New YorkAges 18–70 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
New York, New YorkAges 16–80 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
New York, New YorkAges 18 years+ - NCT06918808RecruitingPhase 2
Stem cell therapy for Crohn's fistula healing
This trial tests if a special stem cell treatment (called DB-3Q bmMSC-EVs) can help heal fistulas caused by Crohn's disease. It's for people who have already tried other treatments and still have actively draining fistulas.
New York, New YorkAges 18–75 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
New York, New YorkAges 16–80 - NCT04263831RecruitingPhase 1/Phase 2
Low-dose IL-2 to treat Crohn’s disease flare-ups
This trial tests a low dose of IL-2 to reduce inflammation and help control Crohn’s disease symptoms. It’s for people whose Crohn’s disease hasn’t responded to at least one standard treatment or who need steroids to stay under control.
New York, New YorkAges 12–80 - NCT05230173Recruiting
Treat to endoscopic remission in inflammatory bowel disease
This study tests whether switching to a different treatment for inflammatory bowel disease (IBD) can achieve healing of the gut lining. It is for people whose symptoms are under control but who still have significant inflammation in their bowel.
New York, New YorkAges 18 years+ - NCT05781152RecruitingPhase 4
Testing how new Crohn’s imaging and scopes predict outcomes
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
New York, New YorkAges 6–17 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
New York, New YorkAges 2–17 - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
New York, New YorkAges 2–17 - NCT06001450Recruiting
Plastics and toxins in pregnant women and families
This study looks at how plastics and toxins in the environment might affect inflammation in the gut, especially in pregnant women with Crohn's disease and their families. It will help doctors understand if these chemicals play a role in bowel inflammation during pregnancy.
New York, New YorkAges 18 years+ - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
New York, New YorkAges 2–19 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Brooklyn, New YorkAges 16–80 - NCT06424769Enrolling by invitation
Managing Inflammatory Bowel Disease with Text Message Surveys
This study aims to improve care and reduce health gaps for people with inflammatory bowel disease using text-message surveys to track symptoms and guide better disease management.
Lake Success, New YorkAges 13 years+ - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
New Hyde Park, New YorkAges 2 years+ - NCT04779320RecruitingPhase 3
Vedolizumab for teens with moderate to severe Crohn's
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
New Hyde Park, New YorkAges 2–17
Hear when a new Crohn’s disease trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Crohn’s disease trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting crohn’s disease studies listed above.
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 5 studies
- New York Gastroenterology Associates · 5 studies
- Columbia University Irving Medical Center · 3 studies
- Goryeb Children's Hospital · 3 studies
- Lenox Hill Hospital · 2 studies
- NYU Langone Health · 2 studies
- Stony Brook University Medical Center · 2 studies
- Weill Cornell Medicine · 2 studies
What taking part in a crohn’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting crohn’s disease studies in New York.
Common questions
- Are there crohn’s disease clinical trials near New York?
- Yes. We're currently tracking 46 recruiting crohn’s disease studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a crohn’s disease study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a crohn’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New crohn’s disease studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.